2. Gene
  3. Parp1 - poly (ADP-ribose) polymerase 1 Gene

Parp1 - poly (ADP-ribose) polymerase 1 Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

中文名称：聚 (ADP-核糖) 聚合酶 1

种属: Rattus norvegicus

同用名: ARTD1; Adprt; Parp-1

基因 ID: 25591 | 基因类型: protein coding

关于 Parp1

Primary_assembly 13: 92,307,586-92,339,404 forward strand.mRatBN7.2:CM026986.1

This gene has 1 transcript (splice variant), 211 orthologues, 2 paralogues and is associated with 82 phenotypes. Biased expression in Heart (RPKM 435.6), Spleen (RPKM 27.7) and 9 other tissues.

功能概要

该基因编码的蛋白可启动多种功能，包括 NAD+ ADP-核糖基转移酶活性； R-SMAD结合活性；和雌激素受体结合活性。参与多个过程，包括信号转导的正向调节；调节神经元死亡；和调节含核碱基的化合物代谢过程。位于细胞质和细胞核中。用于研究充血性心力衰竭；大脑中动脉梗塞;和短暂性脑缺血。多种疾病的生物标志物，包括博尔纳病；脑血管疾病（多发）；肾功能衰竭;围产期坏死性小肠结肠炎；和输尿管梗阻。该基因的人类直系同源基因与多种疾病有关，包括关节炎；细菌性脑膜炎;神经退行性疾病（多种）；胃癌;和 2 型糖尿病。与人类 PARP1（聚（ADP-核糖）聚合酶 1）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables several functions, including NAD+ ADP-ribosyltransferase activity; R-SMAD binding activity; and Estrogen Receptor binding activity. Involved in several processes, including positive regulation of signal transduction; regulation of neuron death; and regulation of nucleobase-containing compound metabolic process. Located in cytoplasm and nucleus. Used to study congestive heart failure; middle cerebral artery infarction; and transient cerebral ischemia. Biomarker of several diseases, including borna disease; cerebrovascular disease (multiple); kidney failure; perinatal necrotizing enterocolitis; and ureteral obstruction. Human ortholog(s) of this gene implicated in several diseases, including arthritis; Bacterial meningitis; neurodegenerative disease (multiple); stomach carcinoma; and type 2 diabetes mellitus. Orthologous to human PARP1 (poly(ADP-ribose) polymerase 1). [provided by Alliance of Genome Resources, Apr 2022]

Parp1 基因产物(1)

mRNA Protein Name
NM_013063.2 NP_037195.1 poly [ADP-ribose] polymerase 1
基因本体论
  • 分子功能
  • 生物过程
  • 细胞组分
分子功能 GO 注释 逻辑证据 参考文献 来源
enables NAD binding IDA
IDA: 通过直接分析推断
15857403 RGD
enables NAD+-protein poly-ADP-ribosyltransferase activity IDA
IDA: 通过直接分析推断
15857403 RGD
enables NAD+-protein poly-ADP-ribosyltransferase activity IMP
IMP: 通过突变表型推断
22073128 RGD
enables R-SMAD binding IPI
IPI: 通过物理相互作用推断
22073128 RGD
enables enzyme binding IPI
IPI: 通过物理相互作用推断
19470756 RGD
enables histone deacetylase binding IPI
IPI: 通过物理相互作用推断
19470756 RGD
enables nuclear estrogen receptor binding IPI
IPI: 通过物理相互作用推断
23493398 RGD
enables protein binding IPI
IPI: 通过物理相互作用推断
25625556 RGD
enables transcription regulator activator activity IDA
IDA: 通过直接分析推断
22073128 RGD
enables ubiquitin protein ligase binding IPI
IPI: 通过物理相互作用推断
24842055 RGD
生物过程 GO 注释 逻辑证据 参考文献 来源
involved in DNA damage response IDA
IDA: 通过直接分析推断
15857403 RGD
involved in carbohydrate biosynthetic process IDA
IDA: 通过直接分析推断
15857403 RGD
involved in cellular response to amyloid-beta IMP
IMP: 通过突变表型推断
21616968 RGD
involved in cellular response to nerve growth factor stimulus IDA
IDA: 通过直接分析推断
16093393 RGD
involved in cellular response to transforming growth factor beta stimulus IEP
IEP: 通过表达模式推断
22073128 RGD
involved in cellular response to zinc ion IEP
IEP: 通过表达模式推断
23582235 RGD
involved in positive regulation of SMAD protein signal transduction IMP
IMP: 通过突变表型推断
22073128 RGD
involved in positive regulation of cardiac muscle hypertrophy IMP
IMP: 通过突变表型推断
25625556 RGD
involved in positive regulation of intracellular estrogen receptor signaling pathway IMP
IMP: 通过突变表型推断
23493398 RGD
involved in positive regulation of mitochondrial depolarization IMP
IMP: 通过突变表型推断
21616968 RGD
involved in positive regulation of myofibroblast differentiation IMP
IMP: 通过突变表型推断
23260200 RGD
involved in positive regulation of protein localization to nucleus IMP
IMP: 通过突变表型推断
22073128 RGD
involved in positive regulation of transcription by RNA polymerase II IMP
IMP: 通过突变表型推断
22073128 RGD
involved in protein autoprocessing IDA
IDA: 通过直接分析推断
16093393 RGD
involved in regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway IMP
IMP: 通过突变表型推断
17347665 RGD
involved in response to aldosterone IEP
IEP: 通过表达模式推断
14994994 RGD
involved in response to gamma radiation IEP
IEP: 通过表达模式推断
14994994 RGD
involved in signal transduction involved in regulation of gene expression IMP
IMP: 通过突变表型推断
22073128 RGD
involved in transforming growth factor beta receptor signaling pathway IMP
IMP: 通过突变表型推断
22073128 RGD
细胞组分 GO 注释 逻辑证据 参考文献 来源
located in nucleus IDA
IDA: 通过直接分析推断
22073128 RGD
EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Parp1 蛋白结构

PLN03123

PLN03123: cl33639 (8 - 1009)

  • 0
  • 200
  • 400
  • 600
  • 800
  • 1014 a.a.
蛋白主名 其他名称

poly [ADP-ribose] polymerase 1

ADP-ribosyltransferase (NAD+

ADP-ribosyltransferase (NAD+

poly (ADP-ribose) polymerase)

ADP-ribosyltransferase 1

ADP-ribosyltransferase diphtheria toxin-like 1

ADPRT 1

DNA ADP-ribosyltransferase PARP1

NAD(+) ADP-ribosyltransferase 1

poly (ADP-ribose) polymerase family, member 1

poly (ADP-ribose) polymerase)

poly(ADP-ribose) polymerase PARP-1

poly[ADP-ribose] synthase 1

poly[ADP-ribose] synthetase 1

protein poly-ADP-ribosyltransferase PARP1

相关产品

Approval
生物活性分子 (14)
目录号 产品名 作用方式
纯度 是否罕见病
HY-10162 Olaparib Inhibitor 99.98% 是
HY-16106 Talazoparib Inhibitor 99.89% 否
HY-10619 Niraparib Inhibitor 99.96% 是
HY-10617A Rucaparib Inhibitor 99.97% 是
HY-114778 Fluzoparib Inhibitor 99.85% 否
HY-10619B Niraparib tosylate Inhibitor 99.99% 是
HY-10617 Rucaparib phosphate Inhibitor 99.76% 是
HY-10619A Niraparib hydrochloride Inhibitor 99.41% 是
HY-102003 Rucaparib monocamsylate Inhibitor 99.82% 是
HY-10619E Niraparib tosylate hydrate Inhibitor 99.97% 是
HY-102003A Rucaparib camsylate Inhibitor / 否
HY-10617C Rucaparib tartrate Inhibitor / 否
HY-10617B Rucaparib hydrochloride Inhibitor / 否
HY-10617D Rucaparib acetate Inhibitor / 否
Clinical Phase
生物活性分子 (12)
目录号 产品名 作用方式
纯度 Phase
HY-122661 Mefuparib hydrochloride Inhibitor 98.94% Phase 4
HY-10129 Veliparib Inhibitor 99.78% Phase 3
HY-12032 AG14361 Inhibitor 99.44% Phase 3
HY-12015 Iniparib Inhibitor 99.82% Phase 3
HY-10130 Veliparib dihydrochloride Inhibitor 99.98% Phase 3
HY-132167 Saruparib Inhibitor 99.76% Phase 2
HY-12418 Stenoparib Inhibitor ≥98.0% Phase 2
HY-137457A Venadaparib hydrochloride Inhibitor / Phase 2
HY-105303 CEP-9722 Inhibitor / Phase 2
HY-13536 AZD-2461 Inhibitor 99.88% Phase 1
HY-13326 ASP3026 99.88% Phase 1
HY-115552 Simmiparib Inhibitor 99.51% Phase 1
Pre-clinical Phase
生物活性分子 (80)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-15147 XAV-939 Inhibitor 99.91% 否
HY-13594 Chlorin e6 98.31% 否
HY-13688A PJ34 Inhibitor 98.11% 否
HY-139156 SK-575 Inhibitor 99.51% 否
HY-150207 RBN-3143 Inhibitor 99.24% 否
HY-13688 PJ34 hydrochloride Inhibitor 99.91% 否
HY-N3584 Paris saponin VII Inhibitor 99.96% 否
HY-N0213 Peiminine 99.94% 否
HY-130644 iRucaparib-AP6 Degrader 99.27% 否
HY-14478 UPF 1069 Inhibitor 99.10% 否
HY-148566 OUL232 Inhibitor 99.86% 否
HY-100225 ME0328 Inhibitor 99.64% 否
HY-12975 AZ6102 Inhibitor 99.65% 否
HY-137457 Venadaparib Inhibitor 98.11% 否
HY-19351 MN-64 Inhibitor 99.61% 否
HY-18954 NMS-P118 Inhibitor 99.78% 否
HY-10619D Niraparib (R-enantiomer) Inhibitor 99.69% 否
HY-123851 MSC2504877 Inhibitor 98.50% 否
HY-156419 PARP7-IN-16 Inhibitor 99.91% 否
HY-132297A PARP1-IN-5 dihydrochloride Inhibitor 97.56% 否
HY-108632 BYK204165 Inhibitor 98.66% 否
HY-16106A (8R,9S)-Talazoparib Inhibitor 98.28% 否
HY-117889 PARP14 inhibitor H10 Inhibitor 98.04% 否
HY-10614 A-966492 Inhibitor 99.95% 否
HY-114324 PROTAC PARP1 degrader Inhibitor 99.74% 否
HY-128599 NMS-P515 Inhibitor 98.18% 否
HY-148754 PARP10-IN-3 Inhibitor 98.89% 否
HY-105692 DR2313 Inhibitor 99.66% 否
HY-155993 YCH1899 Inhibitor 99.39% 否
HY-147886 PARP1-IN-11 Inhibitor 98.58% 否
HY-156419A PARP7-IN-16 free base Inhibitor / 否
HY-164475 PARP1-IN-29 Inhibitor / 否
HY-149800 PARP-1-IN-3 Inhibitor 99.30% 否
HY-133124 PARP/PI3K-IN-1 Inhibitor 99.43% 否
HY-147027 PARP-1-IN-2 Inhibitor 98.80% 否
HY-158045 PROTAC PARP1 degrader-1 Inhibitor 99.86% 否
HY-148753 PARP10-IN-2 Inhibitor 98.02% 否
HY-132297 PARP1-IN-5 Inhibitor / 否
HY-W294889 OUL245 Inhibitor / 否
HY-146336 PARP1/2/TNKS1/2-IN-1 Inhibitor / 否
HY-150765 PARP1-IN-12 Inhibitor / 否
HY-168094 PARP1-IN-30 Inhibitor / 否
HY-100847 AZ0108 Inhibitor / 否
HY-161868 DLC-50 Inhibitor / 否
HY-162114 PARP1-IN-18 Inhibitor / 否
HY-146160 PARP-1/HDAC-IN-1 Inhibitor / 否
HY-158680 PARP1-IN-21 Inhibitor / 否
HY-163817 PARP1/2-IN-3 Inhibitor / 否
HY-148710 ARTD10/PARP10-IN-2 Inhibitor / 否
HY-147030 PARP1-IN-8 Inhibitor 99.29% 否
HY-150613 PARP1/BRD4-IN-2 Inhibitor / 否
HY-149001 PARP1-IN-9 Inhibitor / 否
HY-149003 PARP1-IN-10 Inhibitor / 否
HY-15046 EB-47 Inhibitor / 否
HY-161083 PARP/EZH2-IN-2 Inhibitor / 否
HY-136489A KU-0058948 hydrochloride Inhibitor / 否
HY-146548 Anticancer agent 43 Inducer 98.58% 否
HY-164926 PARP1-IN-33 Inhibitor / 否
HY-161517 PARP1-IN-20 Inhibitor / 否
HY-161372 PARP1/c-Met-IN-1 Inhibitor / 否
HY-158334 NDs-IN-1 Inhibitor / 否
HY-145471A KSQ-4279 (gentisate) Inhibitor / 否
HY-148709 ARTD10/PARP10-IN-1 Inhibitor / 否
HY-105253 PARP-2/1-IN-2 Inhibitor / 否
HY-144338 PARP1/BRD4-IN-1 Inhibitor / 否
HY-132885 PARP/EZH2-IN-1 Inhibitor / 否
HY-169299 TOPOI/PARP-1-IN-2 Inhibitor / 否
HY-145749 PARPYnD Inhibitor / 否
HY-163658 PARP-1-IN-23 Inhibitor / 否
HY-161606 PARP-1/2/7-IN-1 Inhibitor / 否
HY-158681 PARP1-IN-22 Inhibitor / 否
HY-147101 SK-575-NEG Inhibitor / 否
HY-155766 PARP1-IN-14 Inhibitor / 否
HY-157137 PARP1-IN-17 / 否
HY-169170 PARP1/BRD4-IN-3 Inhibitor / 否
HY-14477 UPF-1035 Inhibitor / 否
HY-123232 KU-0058684 Inhibitor / 否
HY-117423 ST7710AA1 Inhibitor / 否
HY-115862 Benzo[c][1,8]naphthyridin-6(5H)-one Inhibitor / 否
HY-U00223 WD2000-012547 Inhibitor / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens Parp1 NCBI NCBI:142
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z